MUVON is excited to announce that our consortium has been awarded an Innosuisse grant, marking a major milestone on our journey to scale out manufacturing and accelerate the path toward a commercial product. Having achieved our positive Phase 2 clinical milestone, we are now concentrating our development efforts on enhanced standardization of the manufacturing process to ensure clinical and commercial scalability and robustness, which is the focus of this Innosuisse grant.
Invest in us to be part of a groundbreaking journey toward innovative, life-changing muscle regeneration therapies, addressing a massive global market with scalable solutions.
